Otezla 30 mg, originated for the treatment of adult patients with oral ulcers related to BD (Behçet's disease) who are recipients of systemic therapy. The otezla 30 mg, alone or together with agent DMARDs, is used to treat PsA (active psoriatic arthritis) in adult patients with an inadequate response or who have been not tolerant to earlier DMARD therapy. Otezla 30 mg is also used to treat moderate/severe chronic plaque psoriasis in adult recipients who are unsuccessful to respond to or who have a contraindication to or are not tolerant to the other existing systemic therapy including methotrexate, cyclosporine, and PUVA (Ultraviolet-A Light).